Ablative treatment for cervical precancer in HIV-positive women in Mozambique
Official title: A Randomized Clinical Trial to Assess the Effectiveness of Ablative Treatments for Cervical Cancer Risk Reduction in HIV+ Women living in Mozambique
Funded at University of Tx Md Anderson Can Ctr · NIH-11535374 · Data updated 2026-11-12
A randomized trial tests whether thermal ablation is as effective as the standard procedure in preventing cervical precancer progression among HIV-positive women in Mozambique.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | May 12, 2020 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $458,708 |
| NIH project number | 3U01CA239921-06S1 |
| Project ID | NIH-11535374 on NIH RePORTER |
Who could benefit from this research
✓Could help
HIV-positive women with CIN 2/3 in Mozambique or similar LMIC settings.
✕Less likely to help
Women without CIN 2/3 or who do not meet trial criteria may not receive direct benefit.
What this research studies
This study compares two treatment options for high-grade cervical precancer in women who are living with HIV in Mozambique. Participants will be screened for high-risk HPV and then receive either thermal ablation or the standard loop electrosurgical excision procedure to treat CIN 2/3. The trial will monitor outcomes and safety to determine which method works best in this immunosuppressed population. Results could influence treatment choices and cervical cancer prevention strategies in similar settings.
Why it matters
Potential benefit: If successful, the trial could identify a simpler, equally effective treatment option that improves outcomes for HIV-positive women at risk of cervical cancer.
How similar studies have gone: Previous evidence in immunocompetent women suggests both treatments can be effective, but data in HIV-positive populations are limited.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Schmeler, Kathleen — University of Tx Md Anderson Can Ctr
- Study coordinator: Schmeler, Kathleen
Related research
Other NIH-funded projects on the same topics.
-
Community and digital tools to reduce HPV and cervical cancer burden
A nurse or health team will test a community-based, digital strategy to help girls and young women, especially in rural areas, get HPV vaccination and cervical cancer prevention services.
-
Community and digital tools to reduce HPV and cervical cancer in women with HIV
A community- and digital-technology program aims to help girls and young women, including those with HIV, get more HPV vaccination and cervical cancer prevention services.
-
mSaada: a mobile tool to boost cervical cancer screening in western Kenya
A mobile app helps community health volunteers manage cervical cancer screening tasks and follow-up for women in low-resource areas.
-
Globally useful predictor for cervical cancer treatment response
This project aims to develop a simple predictive signature to personalize treatment for locally advanced cervical cancer using easy tests and imaging.
-
HPV self-collection in HIV care to screen for cervical cancer in Ethiopia
A patient-centered program tests a simple HPV self-collection approach within HIV clinics in Ethiopia to help detect cervical cancer earlier.
-
Hybrid approach to boost cervical cancer screening in Uganda
A tested, community-driven program helps Ugandan women encourage their peers to get free VIA cervical cancer screening.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.